The District Court of The Hague (Provisions Judge) has rejected Novartis’ application, based on a patent application, for a preliminary injunction (PI), meaning Mylan can market its generic drug containing fingolimod in the Netherlands at least prior to the grant of the patent. The EPO’s Technical Board of Appeal had recently cleared the way for the granting of the patent-in-suit.
BarentsKrans represents Mylan (which is part of the Viatris group of companies) in this case. BarentsKrans has been acting for Mylan for more than 20 years. This recent case illustrated our close partnership with this leading international pharmaceutical company. The BarentsKrans team is led by Jaap Bremer, who is assisted by Allard van Duijn and Marleen van den Horst.